Matinas BioPharma News

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. With Antifungal Expert Dr. David S. Perlin

BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal

GlobeNewswireJun 13 07:00 ET

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersAnitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares incre

BenzingaJun 5 16:31 ET

Express News | Matinas BioPharma Says New In Vitro Data Showing LNC Platform Delivering Small Oligonucleotides Presented At TIDES USA 2024

BenzingaMay 16 07:32 ET

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal

GlobeNewswireMay 16 07:00 ET

Buy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal Candidate

TipRanksMay 11 12:25 ET

Q1 2024 Matinas BioPharma Holdings Inc Earnings Call

Yahoo FinanceMay 10 13:22 ET

Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 19:47 ET

Express News | Matinas BioPharma Holdings Inc - Recent $10 Mln Financing Expected to Fund Planned Development Programs and Operations Into Q2 of 2025

ReutersMay 9 16:34 ET

Express News | Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

ReutersMay 9 16:05 ET

Express News | Matinas BioPharma Q1 Basic EPS USD -0.03

ReutersMay 9 16:05 ET

Express News | Matinas BioPharma Q1 Net Income USD -5.824 Million

ReutersMay 9 16:05 ET

Matinas BioPharma 1Q Loss/Shr 3c >MTNB

Matinas BioPharma 1Q Loss/Shr 3c >MTNB

Dow JonesMay 9 16:05 ET

Matinas BioPharma | 10-Q: Quarterly report

SEC announcementMay 9 16:04 ET · Announcements

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies u

GlobeNewswireMay 7 08:00 ET

Express News | Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

ReutersMay 2 07:00 ET

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden and improvement in lung infectionBEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas Bi

GlobeNewswireApr 30 08:00 ET

Express News | Matinas BioPharma Holdings Inc : Alliance Global Partners Initiates Coverage With Buy Rating and $0.6 Target Price

ReutersApr 26 08:51 ET

Matinas BioPharma's Multi-Million Share Sale and Lock-Up Deal

TipRanksApr 5 07:12 ET

Express News | Matinas BioPharma Prices $10M Registered Direct Offering At A Combined Offering Price Of $0.30 Per Share And Accompanying Warrant

Moomoo 24/7Apr 3 08:34 ET

Matinas BioPharma Prices $10 Million Registered Direct Offering

BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on delivering groundbreaking

GlobeNewswireApr 3 08:30 ET